Skip to main content
. Author manuscript; available in PMC: 2015 Jul 29.
Published in final edited form as: J Cell Biochem. 2014 Mar;115(3):498–509. doi: 10.1002/jcb.24684

Fig. 6.

Fig. 6

Suppressing ErbB2 down regulates GLS1 expression in human breast cancer cells. A: Knockdown of ErbB2 down-regulates GLS1 levels in SK-BR-3 and MDA-MB-453 cells. Twenty-four hours after transfection, protein levels of ErbB2 and GLS1 in SK-BR-3 and MDA-MB-453 cells were examined by Western blots. B: Trastuzumab represses the expression of GLS1. SK-BR-3 and MDA-MB-453 cells were treated with trastuzumab (50 or 100 mg/ml) for 24 h. Protein levels of ErbB2 and GLS1 were determined by Western blotting. The numbers under the blots are quantification of each detected bands; ErbB2, GLS1, or α-tubulin of control group were set at 1.00, treated groups were compared to the control group. C,D: Inhibition or knockdown of p65 reduces GLS1 expression in ErbB2-positive breast cancer cells. NF-κB activity in SK-BR-3 and MDA-MB-453 cells were inhibited by treat cells with 5 and 10mM BAY 11-7082, or by siRNA knockdown. GLS1 expression levels and the p65 knockdown effects were monitored by Western blotting analysis.